First-line NSCLC data reported ahead of ASCO

Merck & Co. Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE) and Bristol-Myers Squibb Co. (NYSE:BMY) each reported Phase III data for their first-line non-small cell lung cancer (NSCLC) programs in abstracts released ahead of the American Society of Clinical Oncology meeting in Chicago.

Merck’s interim analysis of the first 204 patients in the Phase III KEYNOTE-407 trial

Read the full 544 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers